BioPharmX Corp (BPMX) was Initiated by Maxim Group to “Buy” and the brokerage firm has set the Price Target at $3. Maxim Group advised their investors in a research report released on Apr 15, 2016.
Many Wall Street Analysts have commented on BioPharmX Corp. H.C. Wainwright Initiated BioPharmX Corp on Apr 7, 2016 to “Buy”, Price Target of the shares are set at $3.
BioPharmX Corp closed down -0.038 points or -4.09% at $0.89 with 2,13,005 shares getting traded on Monday. Post opening the session at $0.9301, the shares hit an intraday low of $0.86 and an intraday high of $1.05 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Jan 15, 2016, Stephen Morlock (director) purchased 12,000 shares at $1.52 per share price.
BioPharmX Corporation is a specialty pharmaceutical company focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter or OTC products that address markets in women’s health and dermatology. The Company’s portfolio of product candidates includes two clinical stage product candidates: BPX01 a topical antibiotic for the treatment of acne and BPX03 a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition or FBC and cyclic mastalgia. The Company’s commercial product VI2OLET iodine is an OTC dietary supplement molecular iodine tablet that promotes breast health and is for the alleviation of benign breast pain associated with fibrocystic breast condition or FBC. The Company has one wholly owned subsidiary BioPharmX Inc.